| Clinical implications of pharmacogenetic variation on the effects of statins SDS Maggo, MA Kennedy, DWJ Clark Drug Safety 34, 1-19, 2011 | 93 | 2011 |
| Pharmacogenetics of statin-induced myotoxicity PS Kee, PKL Chin, MA Kennedy, SDS Maggo Frontiers in Genetics 11, 575678, 2020 | 51 | 2020 |
| Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand M Harrison-Woolrych, S Maggo, M Tan, R Savage, J Ashton Drug safety 35, 33-43, 2012 | 44 | 2012 |
| Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplications Y Liau, S Maggo, AL Miller, JF Pearson, MA Kennedy, SL Cree Pharmacogenomics 20 (14), 1033-1047, 2019 | 42 | 2019 |
| Neuroprotective effect of hydroxypropyl-β-cyclodextrin in hypoxia-ischemia JR Rivers, SDS Maggo, JC Ashton NeuroReport 23 (3), 134-138, 2012 | 28 | 2012 |
| Impact of new genomic technologies on understanding adverse drug reactions SDS Maggo, RL Savage, MA Kennedy Clinical Pharmacokinetics 55, 419-436, 2016 | 25 | 2016 |
| Pharmacogenetics of angiotensin‐converting enzyme inhibitor‐induced angioedema Y Liau, I Chua, MA Kennedy, S Maggo Clinical & Experimental Allergy 49 (2), 142-154, 2019 | 22 | 2019 |
| The three ps: Psychiatry, pharmacy, and pharmacogenomics, a brief report from New Zealand SDS Maggo, KLV Sycamore, AL Miller, MA Kennedy Frontiers in psychiatry 10, 690, 2019 | 17 | 2019 |
| Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig S Maggo, JC Ashton European journal of pharmacology 723, 294-304, 2014 | 17 | 2014 |
| Common CYP2D6, CYP2C9, and CYP2C19 gene variants, health anxiety, and neuroticism are not associated with self-reported antidepressant side effects S Maggo, MA Kennedy, ZA Barczyk, AL Miller, JJ Rucklidge, RT Mulder, ... Frontiers in Genetics 10, 1199, 2019 | 16 | 2019 |
| A New Zealand platform to enable genetic investigation of adverse drug reactions SDS Maggo, EW Chua, P Chin, S Cree, J Pearson, M Doogue, ... The New Zealand Medical Journal (Online) 130 (1466), 62-69, 2017 | 13 | 2017 |
| Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus PS Kee, SDS Maggo, MA Kennedy, ML Barclay, AL Miller, K Lehnert, ... Frontiers in Genetics 13, 869160, 2022 | 12 | 2022 |
| Personalised prescribing in psychiatry: Has pharmacogenomics delivered on its promise? JA Foulds, SDS Maggo, MA Kennedy Australian & New Zealand Journal of Psychiatry 50 (6), 509-510, 2016 | 12 | 2016 |
| The effect of statins on performance in the Morris water maze in guinea pig S Maggo, D Clark, JC Ashton European journal of pharmacology 674 (2-3), 287-293, 2012 | 12 | 2012 |
| Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population A Adehin, OO Bolaji, S Maggo, MA Kennedy Drug Metabolism and Personalized Therapy 32 (1), 39-47, 2017 | 10 | 2017 |
| The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses PS Kee, SDS Maggo, MA Kennedy, PKL Chin Frontiers in Pharmacology 14, 1080117, 2023 | 9 | 2023 |
| Long fragment polymerase chain reaction EW Chua, S Maggo, MA Kennedy PCR: Methods and Protocols, 65-74, 2017 | 9 | 2017 |
| A multiplex pharmacogenetics assay using the MinION nanopore sequencing device Y Liau, SL Cree, S Maggo, AL Miller, JF Pearson, PA Gladding, ... Pharmacogenetics and Genomics 29 (9), 207-215, 2019 | 7 | 2019 |
| Allelic diversity of the pharmacogene CYP2D6 in New Zealand Māori and Pacific peoples LM Hitchman, A Faatoese, TR Merriman, AL Miller, Y Liau, OEE Graham, ... Frontiers in genetics 13, 1016416, 2022 | 6 | 2022 |
| A proof-of-principle study of the short-term effects of 3, 4-methylenedioxymethamphetamine (MDMA) on tinnitus and neural connectivity GD Searchfield, T Poppe, M Durai, M Jensen, MA Kennedy, S Maggo, ... International Journal of Neuroscience 130 (7), 671-682, 2020 | 6 | 2020 |
Martin A KennedyResearch Professor, University of Otago, Christchurch, New ZealandEmail verificata su otago.ac.nz